BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17568484)

  • 1. The need for public education: "Surveillance and risk reduction strategies" for women at risk for carrying BRCA gene mutations.
    Nisker JA
    J Obstet Gynaecol Can; 2007 Jun; 29(6):510-1. PubMed ID: 17568484
    [No Abstract]   [Full Text] [Related]  

  • 2. Educational-support groups for BRCA mutation carriers satisfy need for information but do not affect emotional distress.
    Landsbergen KM; Brunner HG; Manders P; Hoogerbrugge N; Prins JB
    Genet Couns; 2010; 21(4):423-37. PubMed ID: 21290972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 24366402
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
    Moyer VA;
    Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 25006622
    [No Abstract]   [Full Text] [Related]  

  • 6. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
    Doren A; Vecchiola A; Aguirre B; Villaseca P
    Climacteric; 2018 Dec; 21(6):529-535. PubMed ID: 30295091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Summaries for patients. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: U.S. Preventive Services Task Force recommendations.
    Ann Intern Med; 2005 Sep; 143(5):I47. PubMed ID: 16144889
    [No Abstract]   [Full Text] [Related]  

  • 9. Improving surveillance and quality of life of BRCA mutation carriers.
    Loman N; Borg A
    J Clin Oncol; 2010 Aug; 28(22):e376-7. PubMed ID: 20458044
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.
    Nelson HD; Huffman LH; Fu R; Harris EL;
    Ann Intern Med; 2005 Sep; 143(5):362-79. PubMed ID: 16144895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choices--and uncertainties--for women with BRCA mutations.
    Couzin J
    Science; 2003 Oct; 302(5645):592. PubMed ID: 14576419
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.
    Nelson HD; Pappas M; Zakher B; Mitchell JP; Okinaka-Hu L; Fu R
    Ann Intern Med; 2014 Feb; 160(4):255-66. PubMed ID: 24366442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scaring up patients.
    Ortolon K
    Tex Med; 2008 Aug; 104(8):43-6. PubMed ID: 19306543
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic risk assessment and BRCA mutation testing.
    Ormond KE; Bellcross C; Weissman S
    Ann Intern Med; 2006 Feb; 144(4):303-4; discussion 304. PubMed ID: 16490919
    [No Abstract]   [Full Text] [Related]  

  • 15. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement.
    U.S. Preventive Services Task Force
    Ann Intern Med; 2005 Sep; 143(5):355-61. PubMed ID: 16144894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Counseling the at risk patient in the BRCA1 and BRCA2 Era.
    Barnes-Kedar IM; Plon SE
    Obstet Gynecol Clin North Am; 2002 Jun; 29(2):341-66, vii. PubMed ID: 12108833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.
    Paluch-Shimon S; Cardoso F; Sessa C; Balmana J; Cardoso MJ; Gilbert F; Senkus E;
    Ann Oncol; 2016 Sep; 27(suppl 5):v103-v110. PubMed ID: 27664246
    [No Abstract]   [Full Text] [Related]  

  • 19. Reproductive issues for women with BRCA mutations.
    Friedman LC; Kramer RM
    J Natl Cancer Inst Monogr; 2005; (34):83-6. PubMed ID: 15784831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-reducing salpingo-oophorectomy for BRCA mutation carriers.
    Haldar K; Crawford R
    Maturitas; 2010 Nov; 67(3):290. PubMed ID: 20869823
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.